

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

RECOMBINANT HERPES ZOSTER VACCINE (SYS6052) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Recombinant Herpes Zoster Vaccine (SYS6052) (the “**Product**”), a Class 1 innovative prophylactic biological product developed by the Group, has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct relevant clinical trials in the U.S. Previously, the Product was approved by the National Medical Products Administration (NMPA) of the People’s Republic of China in July 2026 to conduct clinical trials in China.

The Product is the first recombinant protein vaccine product of the Company approved for clinical trials. It consists of the varicella-zoster virus (VZV) glycoprotein E (gE) antigen and a novel nano-adjuvant system independently developed by the Group. Through the optimisation of the antigen and nano-adjuvant system, the Product induces robust humoral and cellular immune responses, providing a more diversified prevention option for the applicable population. In preclinical studies, the Product demonstrated a favourable safety and efficacy profile.

The indication for the approved clinical trial is the prevention of herpes zoster and its complications in adults aged 50 years and older. This clinical trial approval in the U.S. marks another important achievement for the Group in the field of recombinant protein vaccines, laying a solid foundation for the global development of prophylactic vaccine products, including the recombinant herpes zoster vaccine.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 29 September 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.